$BCLI new volume gap & candle. $4.76 called 10/7
Post# of 98044
Posted On: 01/01/2015 7:52:45 PM
$BCLI new volume gap & candle . $4.76
called 10/7/14 $3.87
Nasdaq CM
56% Buy Composite rating
Website
Shares Outstanding: 15.28M
Float: 12.11M
% Held by Insiders: 0.62%
% Held by Institutions: 0.20%
Shares Short (as of Nov 28, 2014): 6.45K
Short Ratio (as of Nov 28, 2014): 0.10
Short % of Float (as of Nov 28, 2014): 0.10%
Shares Short (prior month): 20.44K
10-Q 11/13/14
Summary
Recent trades
Headlines
Wednesday, December 31, 2014
Brainstorm Cell Therapeutics (BCLI) Stock Rises Today Ahead of ALS Treatment Trial Data Releaseat TheStreet (Wed, Dec 31)
Monday, December 22, 2014
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015PR Newswire (Mon, Dec 22)
Monday, December 15, 2014
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist OfficePR Newswire (Mon, Dec 15)
Friday, November 21, 2014
BRAINSTORM CELL THERAPEUTICS INC. FinancialsEDGAR Online Financials (Fri, Nov 21)
Saturday, November 15, 2014
10-Q for Brainstorm Cell Therapeutics, Inc.Company Spotlight (Sat, Nov 15)
Thursday, November 13, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemEDGAR Online (Thu, Nov 13)
BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate UpdatePR Newswire (Thu, Nov 13)
Wednesday, November 5, 2014
BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13PR Newswire (Wed, Nov 5)
Tuesday, November 4, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial StatementsEDGAR Online (Tue, Nov 4)
Thursday, October 16, 2014
Brainstorm CEO Offers Investors a Frank Outlook for ALS Therapyat TheStreet (Thu, Oct 16)
Tuesday, October 7, 2014
BCLI: BrainStorm Shares Remain An Attractive InvestmentZacks Small Cap Research (Tue, Oct 7)
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALSPR Newswire (Tue, Oct 7)
Monday, October 6, 2014
BrainStorm Reports Last Patient Visit in Phase 2a ALS StudyPR Newswire (Mon, Oct 6)
Tuesday, September 30, 2014
BrainStorm Completes Uplisting to the NASDAQ Capital MarketMarketwired (Tue, Sep 30)
Wednesday, September 24, 2014
BrainStorm Receives Approval for Uplisting to the NASDAQ Capital MarketAccesswire (Wed, Sep 24)
Tuesday, September 16, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, AmendmentsEDGAR Online (Tue, Sep 16)
BrainStorm Announces Completion of Reverse Split of Common Stock, a Key Step for Uplisting on the NASDAQAccesswire (Tue, Sep 16)
Tuesday, September 9, 2014
BrainStorm Provides Update on NASDAQ Uplisting ProcessMarketwired (Tue, Sep 9)
Thursday, September 4, 2014
BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment ConferenceAccesswire (Thu, Sep 4)
Wednesday, September 3, 2014
BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS DiseasesAccesswire (Wed, Sep 3)
called 10/7/14 $3.87
Nasdaq CM
56% Buy Composite rating
Website
Shares Outstanding: 15.28M
Float: 12.11M
% Held by Insiders: 0.62%
% Held by Institutions: 0.20%
Shares Short (as of Nov 28, 2014): 6.45K
Short Ratio (as of Nov 28, 2014): 0.10
Short % of Float (as of Nov 28, 2014): 0.10%
Shares Short (prior month): 20.44K
10-Q 11/13/14
Summary
Recent trades
Headlines
Wednesday, December 31, 2014
Brainstorm Cell Therapeutics (BCLI) Stock Rises Today Ahead of ALS Treatment Trial Data Releaseat TheStreet (Wed, Dec 31)
Monday, December 22, 2014
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015PR Newswire (Mon, Dec 22)
Monday, December 15, 2014
BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist OfficePR Newswire (Mon, Dec 15)
Friday, November 21, 2014
BRAINSTORM CELL THERAPEUTICS INC. FinancialsEDGAR Online Financials (Fri, Nov 21)
Saturday, November 15, 2014
10-Q for Brainstorm Cell Therapeutics, Inc.Company Spotlight (Sat, Nov 15)
Thursday, November 13, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemEDGAR Online (Thu, Nov 13)
BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate UpdatePR Newswire (Thu, Nov 13)
Wednesday, November 5, 2014
BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13PR Newswire (Wed, Nov 5)
Tuesday, November 4, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial StatementsEDGAR Online (Tue, Nov 4)
Thursday, October 16, 2014
Brainstorm CEO Offers Investors a Frank Outlook for ALS Therapyat TheStreet (Thu, Oct 16)
Tuesday, October 7, 2014
BCLI: BrainStorm Shares Remain An Attractive InvestmentZacks Small Cap Research (Tue, Oct 7)
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALSPR Newswire (Tue, Oct 7)
Monday, October 6, 2014
BrainStorm Reports Last Patient Visit in Phase 2a ALS StudyPR Newswire (Mon, Oct 6)
Tuesday, September 30, 2014
BrainStorm Completes Uplisting to the NASDAQ Capital MarketMarketwired (Tue, Sep 30)
Wednesday, September 24, 2014
BrainStorm Receives Approval for Uplisting to the NASDAQ Capital MarketAccesswire (Wed, Sep 24)
Tuesday, September 16, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, AmendmentsEDGAR Online (Tue, Sep 16)
BrainStorm Announces Completion of Reverse Split of Common Stock, a Key Step for Uplisting on the NASDAQAccesswire (Tue, Sep 16)
Tuesday, September 9, 2014
BrainStorm Provides Update on NASDAQ Uplisting ProcessMarketwired (Tue, Sep 9)
Thursday, September 4, 2014
BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment ConferenceAccesswire (Thu, Sep 4)
Wednesday, September 3, 2014
BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS DiseasesAccesswire (Wed, Sep 3)
(0)
(0)Scroll down for more posts ▼